110 results
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
.
Patient Assistance Program
ImmunityBio is committed to helping patients access ANKTIVA and will be offering services to overcome access barriers … . ImmunityBio’s Patient Assistance Program will be operational in mid-May. This program is designed to help those in need, ensuring access to ImmunityBio’s
S-3ASR
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
and telephone number:
ImmunityBio, Inc.
3530 John Hopkins Court
San Diego, CA 92121
Attn: Investor Relations
(844) 696-5235
You may also access
424B5
52ryd
24 Jul 23
Prospectus supplement for primary offering
5:12pm
8-K
EX-1.1
z77u9 ktzmt
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-10.1
jb99nf4578q7f01d 2r1
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-1.1
ytbn7zsdv6n4qrelo
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
EX-10.1
4ipnpv 778
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
424B5
efn s3gf7x
12 Dec 22
Prospectus supplement for primary offering
8:08am
8-K
emvdfv0g4bn 6u
15 Nov 22
Regulation FD Disclosure
8:42am